Agilent Secures Expanded FDA Approval for PD-L1 Diagnostic in Esophageal Cancer
Summary
Agilent Technologies has received FDA approval for its PD-L1 IHC 22C3 pharmDx as a companion diagnostic for esophageal or gastroesophageal junction (GEJ) carcinoma. This expanded indication allows the diagnostic to identify patients eligible for treatment with Merck's KEYTRUDA, a leading anti-PD-1 therapy. This marks the eighth FDA-approved companion diagnostic indication for this product with KEYTRUDA, strengthening Agilent's position in precision oncology diagnostics. The approval is a positive development, expanding the market opportunity for Agilent's diagnostic portfolio and supporting its growth in the clinical diagnostics division. Investors will watch for the commercial rollout and adoption rates of this expanded indication.
At the time of this announcement, A was trading at $113.32 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.9B. The 52-week trading range was $96.43 to $160.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.